Allocation and dynamics of inducible nitric oxide synthase expression in patients with rectal cancer under the influence of neoadjuvant chemoradiotherapy and their relationship with efficiency of polyradiomodification with the usage of L-arginine.

Authors

  • V. V. Golotiuk Ivano-Frankivsk National Medical University, Ukraine
  • M. M. Bagriy Ivano-Frankivsk National Medical University, Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2016.3.99-103

Keywords:

rectal carcinoma, medical pathomorphosis, chemoradiation therapy, nitric oxide, inducible nitric oxide synthase, immunohistochemistry

Abstract

Background. Considering the importance of nitric oxide in the malignant growth pathogenesis, researchers are actively exploring properties of nitric oxide synthesis biological systems in colorectal cancer tumors. However, literature data according the characteristics of iNOS expression in colorectal cancer and its prognostic and predictive value is ambiguous. Objective: to define the features of iNOS expression in intact colon and rectal cancer tissues before treatment and after the course of neoadjuvant chemoradiotherapy, including the background of the drug precursor of nitric oxide. Methods. iNOS expression indexes were determined by immunohistochemistry in the biopsy and surgical material in 24 patients with adenocarcinoma of the rectum stage II-III before and after neoadjuvant chemoradiotherapy. Results. It was revealed 4.5 times higher levels of iNOS expression in the rectal cancer tumor compared with intact mucosa. Rectal cancer iNOS is expressed in tumor parenchyma cells and in tumor stroma, the level of immunosignal in stroma is 24% higher compared with parenchyma. Positive correlation (r= 0.74; р<0.05) of iNOS expression in the tumor with metastatic lesion of regional lymph nodes was established in rectal cancer patients. High expression level of iNOS in rectal cancer tissue is a positive predictive factor for the effectiveness of radiation therapy on the background polyradiomodification using tegafur and L-arginine. Conclusion. Discovered peculiarities of iNOS expression indicate the advisability of taking into account this marker when planning neoadjuvant therapy of patients with rectal cancer and establishing the risk of disease progression.

References

  1. Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol. 2013; 11:118. doi: 10.1186/1477-7819-11-118.
  2. Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol. 2011 Jun; 89(6):873-91. doi: 10.1189/jlb.1010550.
  3. Blaise GA, Gauvin D, Gangal M, Authier S. Nitric oxide, cell signaling and cell death. Toxicology. 2005 Mar 15; 208(2):177-92.
  4. Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics (review). Int J Oncol. 2008 Nov; 33(5):909-27.
  5. Stuehr DJ. Enzymes of the L-arginine to nitric oxide pathway. J Nutr. 2004 Oct; 134(10 Suppl):2748S-2751S; discussion 2765S-2767S.
  6. Rahat MA, Hemmerlein B. Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol. 2013 Jun 18; 4:144. doi: 10.3389/fphys.2013.00144.
  7. Zafirellis K, Zachaki A, Agrogiannis G, Gravani K. Inducible nitric oxide synthase expression and its prognostic significance in colorectal cancer. APMIS. 2010 Feb; 118(2):115-24. doi: 10.1111/j.1600-0463.2009.02569.x.
  8. Gochman E, Mahajna J, Shenzer P, Dahan A, Blatt A, Elyakim R, Reznick AZ. The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. Acta Histochem. 2012 Dec; 114(8):827-35. doi: 10.1016/j.acthis.2012.02.004.

How to Cite

Golotiuk, V. V., & Bagriy, M. M. (2016). Allocation and dynamics of inducible nitric oxide synthase expression in patients with rectal cancer under the influence of neoadjuvant chemoradiotherapy and their relationship with efficiency of polyradiomodification with the usage of L-arginine. Морфологія / Morphologia / Morfologìâ, 10(3), 99–103. https://doi.org/10.26641/1997-9665.2016.3.99-103

Issue

Section

Статті